Clearbridge Strengthens Asian Liquid Biopsy Ties
This article was originally published in Clinica
Executive Summary
Clearbridge BioMedics, the Singapore-based developer of circulating tumor cell capture technology for liquid biopsies, has further strengthened its Asian distributor network. The company has enlisted BGI Shenzhen, the world's largest genome institute, to distribute its ClearCell FX1 system in China, including Hong Kong and Macao.